Proteomics International Laboratories Ltd Secures US Patent for PromarkerEndo Test
Proteomics International secures US patent for its PromarkerEndo endometriosis blood test
The United States Patent and Trademark Office (USPTO) has granted Proteomics International (ASX: PIQ) a patent covering its PromarkerEndo diagnostic blood test for endometriosis. The patent, titled ‘Endometriosis Biomarkers’ (US Patent No. 12674806), secures intellectual property protection in the world’s largest healthcare market.
Announced on 8 July 2026, the grant marks a critical step in the company’s global commercialisation strategy. Patent protection is expected to extend until March 2041, subject to grant and maintenance requirements.
When big ASX news breaks, our subscribers know first
What the patent covers and why the US market matters
The granted patent covers methods of diagnosing endometriosis using specific protein biomarkers measured in blood samples, and using the results to guide treatment selection. This positions the endometriosis diagnostic test for entry into a market where demand for non-invasive diagnostics continues to rise.
The United States represents the largest healthcare market globally, with increasing demand for innovative non-invasive diagnostic technologies that aim to improve patient outcomes and reduce healthcare costs. According to the company, the patent supports commercialisation efforts and underpins the commercialisation pathway, enabling future partnerships and licensing opportunities.
Key details of the granted patent include:
-
Patent title: ‘Endometriosis Biomarkers’
-
Patent number: US Patent No. 12674806
-
Coverage: diagnosis via blood-based protein biomarkers plus treatment guidance
-
Term: expected to extend until March 2041 (subject to grant and maintenance requirements)
David Morris, CEO & Managing Director
“The grant of this patent by the USPTO is a major achievement and an important validation of the novelty and commercial potential of PromarkerEndo. The United States is the world’s largest healthcare market and securing patent protection in this jurisdiction is a critical step in our global commercialisation strategy. This milestone significantly strengthens our position for future partnerships, licensing discussions, and regulatory reimbursement advancement.”
Understanding endometriosis and the PromarkerEndo test
Endometriosis is a common and painful condition that occurs when tissue similar to the lining of the uterus grows in other parts of the body where it does not belong. The condition affects one in nine women and girls, representing a substantial global health burden.
The current method for testing the condition is a surgical laparoscopy, an invasive procedure. Diagnosis typically takes an average of 7 years, a delay that can prolong patient suffering and increase healthcare costs.
PromarkerEndo could provide early screening to rule in or out the need for invasive surgery for women presenting with symptoms of endometriosis. As a simple blood test, it offers a potential alternative to surgical diagnosis.
The test draws on the company’s proprietary Promarker® platform, which searches for protein ‘fingerprints’ in a blood sample. This technology can identify proteins that distinguish between people who have a disease and people who do not, using only a blood test, and is described by the company as a powerful alternative to genetic testing.
Published clinical studies have demonstrated the patented blood test has high accuracy for detecting endometriosis, including in the early stages of the disease [ASX: 30 December 2024, 26 May 2025]. For investors, the combination of a large unmet clinical need and a non-invasive solution points to a significant addressable market.
The next major ASX story will hit our subscribers first
A strengthening global IP position and the commercialisation pathway
The US grant builds on the company’s broader intellectual property strategy. Patent protection for the PromarkerEndo technology has now advanced in two major jurisdictions, Japan and the United States, strengthening the foundation for its commercialisation efforts.
Proteomics International is pursuing patent protection in several additional key jurisdictions. The table below summarises the current status across markets.
| Jurisdiction | Patent Status |
|---|---|
| Japan | Granted |
| United States | Granted (new) |
| Australia | Pursuing |
| Canada | Pursuing |
| China | Pursuing |
| Europe | Pursuing |
| India | Pursuing |
| Singapore | Pursuing |
| South Korea | Pursuing |
A strengthening patent portfolio is central to the investment thesis for a precision diagnostics company. Granted protection underpins future partnerships, supports licensing discussions, and, according to management, strengthens the company’s position for regulatory reimbursement advancement.
The US patent grant feeds directly into a broader commercialisation framework: Proteomics International’s four-test commercial roadmap, outlined in its April 2026 investor presentation, targets a combined Australian and US serviceable market of over one million annual tests, with PromarkerEndo alone accounting for an estimated 410,000 of those.
The US patent grant reinforces Proteomics International’s positioning as a precision diagnostics company addressing a major global unmet need. By securing protection in the world’s largest healthcare market for a non-invasive endometriosis diagnostic test, the company has taken a further step along its stated commercialisation pathway.
Don’t Miss the Next Healthcare Breakthrough on ASX
Big News Blast delivers FREE breaking ASX healthcare news directly to your inbox within minutes of release, complete with in-depth analysis. Join 20,000+ subscribers already staying ahead of the market. Click the “Free Alerts” button at StockWire X to get the next market-moving announcement the moment it drops.